www.aduro.com/about/
www.finanznachrichten.de/...chten-aktien/aduro-biotech-inc.htm
www.finanznachrichten.de/...chten-aktien/aduro-biotech-inc.htm
Anzeige
Meldung des Tages: Hypothekenkapital trifft KI: FUTR expandiert vom Automobilsektor in die 13,5 Bill. Dollar Hypothekenindustrie
Aturo Biotech
Beiträge:
50
Zugriffe: 22.634 / Heute: 3
Zugriffe: 22.634 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +77,02%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +57,45%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +57,41%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +49,90%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +49,85%
BERKELEY, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) announced today that it has entered into a clinical trial agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the safety, tolerability and preliminary efficacy of Aduro's lead LADD immunotherapy, CRS-207, in combination with Incyte's oral indoleamine dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), in patients with ovarian cancer.
The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body's own immune defenses, may provide unique synergies in fighting cancer. Incyte's epacadostat has been shown in vitro and in preclinical tumor models to enhance activities of multiple types of immune cells by reducing the immune suppression characteristic of the tumor microenvironment. Aduro's CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer.
"There's a growing body of evidence and enthusiasm in the field of oncology to combine therapeutic agents with different mechanisms that may result in very powerful approaches to treating tough cancers," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "Incyte is a leader in the field of cancer immunotherapy and we're pleased to join forces with them to study a novel approach to treating ovarian cancer."
Rich Levy, M.D., chief drug development officer of Incyte added, "This clinical trial collaboration with Aduro is an important opportunity to further investigate the therapeutic value of epacadostat in advanced ovarian cancer. Research partnerships like this one help us deliver on our goal of advancing innovative science to improve patients' lives."
The Phase 1/2 trial, which is being funded equally between the two companies, is designed to test combinations of CRS-207 with two dose levels of epacadostat in dose escalation and then will expand to a Phase 2 evaluating the combination at the optimal dose level compared to CRS-207 alone based on safety and tumor biomarkers. The study plans to enroll up to 40 patients in Phase 1 and up to 86 patients in Phase 2 with platinum-resistant ovarian, fallopian or peritoneal cancers. The trial is expected to begin enrolling pat
The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body's own immune defenses, may provide unique synergies in fighting cancer. Incyte's epacadostat has been shown in vitro and in preclinical tumor models to enhance activities of multiple types of immune cells by reducing the immune suppression characteristic of the tumor microenvironment. Aduro's CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer.
"There's a growing body of evidence and enthusiasm in the field of oncology to combine therapeutic agents with different mechanisms that may result in very powerful approaches to treating tough cancers," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "Incyte is a leader in the field of cancer immunotherapy and we're pleased to join forces with them to study a novel approach to treating ovarian cancer."
Rich Levy, M.D., chief drug development officer of Incyte added, "This clinical trial collaboration with Aduro is an important opportunity to further investigate the therapeutic value of epacadostat in advanced ovarian cancer. Research partnerships like this one help us deliver on our goal of advancing innovative science to improve patients' lives."
The Phase 1/2 trial, which is being funded equally between the two companies, is designed to test combinations of CRS-207 with two dose levels of epacadostat in dose escalation and then will expand to a Phase 2 evaluating the combination at the optimal dose level compared to CRS-207 alone based on safety and tumor biomarkers. The study plans to enroll up to 40 patients in Phase 1 and up to 86 patients in Phase 2 with platinum-resistant ovarian, fallopian or peritoneal cancers. The trial is expected to begin enrolling pat
Boerse ist reine Psychologie. Nicht mehr und nicht weniger.
www.finanzen.net/analyse/...erform-Oppenheimer__Co_Inc__561355
www.finanzen.net/analyse/...ech_Buy-Rodman__Renshaw_LLC_610084
endpts.com/...-setback-forces-shift-to-novartis-alliance-now/
Deal mit Eli Lilly
www.zacks.com/stock/news/343765/...ivator-deal-with-eli-lilly
strategisches Update
- Personal um 37% reduziert
- Konzentration auf STING & APRIL pathways
- Entpriorisierung von pLADD, ADU-1604 (Anti-CTLA-4) und ADU-1805 (Anti-SIRPα)
- MK 259 Mio. $
- Partnerschaften mit Eli Lilly, Novartis und Merck
- Ende 2018 Cash ~278 Mio. $
"The reduction in ongoing operating expenses is expected to extend the Company’s cash, cash equivalents and marketable securities into 2022, exclusive of potential future milestone payments from its collaborations with Novartis, Lilly and Merck."
investors.aduro.com/...3&p=irol-newsArticle&ID=2385345
hatten sie rund 80 Mio Aktien out. Mit dem jetzigen Kurs 3,26 eine MK von rund 260Mio$
Um cash, aber auch nur Phase1 Kandidaten.
Um cash, aber auch nur Phase1 Kandidaten.
Aduro meldet Zahlen für Q1/19
- Umsatz 4 Mio. $
- Verlust 23 Mio. $
- Cash 267 Mio. $
- MK 278 Mio. $
investors.aduro.com/news-releases/...news_date_value[min]=2019
Aduro BioTech hat sich entschieden die Phase 1/2 Studie BION-1301 nicht fortzuführen
investors.aduro.com/news-releases/...news_date_value[min]=2019
investors.aduro.com/news-releases/...news_date_value[min]=2019
Phase 1b Daten kamen nicht gut an
seekingalpha.com/news/...t-underwhelming-data-sting-candidate
Hier die Gründe für den Kursverfall
www.zacks.com/stock/news/424607/...pdates-on-cancer-candidate
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Chinook Therapeutics Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 49 | Aturo Biotech | Balu4u | Vassago | 12.06.23 11:43 |